Inside Information: 23andMe and Nightingale Health Announce Strategic Collaboration to Pilot Blood Biomarker Panel

Nightingale Health Plc
Company release, inside information
28 June 2024 at 2:00 p.m. (EEST)

Nightingale Health Plc (“Nightingale Health”), a pioneer in disease risk detection and preventive health (HEL: HEALTH), and 23andMe Holding Co., a leading preventive health and therapeutics company, today announced a strategic collaboration to pilot Nightingale Health’s clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members.

Nightingale’s Remote Health Check accurately measures dozens of biomarkers from a single blood sample, including cholesterols, apolipoproteins and fatty acids like omega-3. Many of these blood biomarkers have established clinical relationships to disease and can help guide important lifestyle interventions – such as diet and exercise. This pilot marks an important milestone in making blood testing more efficient and accessible.

23andMe currently offers its annual members the option for blood testing and provides interactive tools like HealthTracks, a feature that incorporates customer lifestyle choices into calculating a lifetime risk of disease. Blood biomarkers may improve the accuracy of these predictions and provide more direct insight into the kinds of interventions that may be most impactful to a customer’s health.

As part of the pilot, 23andMe will offer up to 5,000 23andMe+ Premium and Total Health members the opportunity to receive blood testing through Nightingale’s Remote Health Check at no cost to them. The pilot will evaluate customer feedback around blood testing, at-home sample collection, and the utility of the data when coupled with 23andMe’s established personal genetics products.

23andMe and Nightingale Health have a shared vision to help individuals identify health risks and prevent disease through proactive testing, treatment, coaching and behavior change. Together, the companies’ technologies allow for a more comprehensive assessment of a customer’s health and continuous tracking of progress toward their goals.

“We are truly impressed with Nightingale Health’s capabilities in blood biomarker testing. Their work with public biobank projects and resulting publications have previewed the exciting potential for metabolomics in prediction. We believe this collaboration will ultimately help our customers lead longer, healthier lives,” said Anne Wojcicki, CEO and Co-Founder of 23andMe. “We are enthusiastic about long-term opportunities that combine the power of our technologies.”

“This collaboration enables a globally unique feature set for 23andMe’s consumer health services. Together, we can help customers track and improve their health with regular blood testing using Nightingale Health’s technology,” said Teemu Suna, CEO and Founder of Nightingale Health. “This marks an important step in the execution of Nightingale Health’s strategy, as it announces an important partnership providing access to the consumer health market.”  

 

For further information, please contact:

Teemu Suna, CEO
[email protected]

 

Certified advisor:

Oaklins Merasco Ltd, tel. +358 9 6129 670

 

 

About Nightingale Health

 

Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

 

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com